logo
logo

Oncopep Completes $11 Million Series D Financing To Continue Clinical Trials And Advance Pipeline Development

Oncopep Completes $11 Million Series D Financing To Continue Clinical Trials And Advance Pipeline Development

12/09/21, 10:37 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$11 million
Round Type
series d
OncoPep, Inc., a developer of transformative immunotherapeutics, announced $11 million in Series D funding. The Series D was led by Tera Science and Kukje Pharma with participation from SX Company and CrystalBioScience.

Company Info

Company
Onco Pep, Inc
Location
cambridge, maryland, united states
Additional Info
OncoPep, Inc. is developing novel immunotherapeutics to prevent the progression of cancer, extend survival, and restore the quality of life of patients. OncoPep's lead program, PVX-410, is an investigational, multi-peptide therapeutic vaccine being evaluated in treating multiple myeloma and triple-negative breast cancer by stimulating an immune response against cancer cells. SOURCE OncoPep, Inc.